Abstract

Aspergillus fumigatus is the leading causative agent of life-threatening invasive aspergillosis in immunocompromised individuals. One antifungal class used to treat Aspergillus infections is the fungistatic echinocandins, semisynthetic drugs derived from naturally occurring fungal lipopeptides. By inhibiting beta-1,3-glucan synthesis, echinocandins cause both fungistatic stunting of hyphal growth and repeated fungicidal lysis of apical tip compartments. Here, we uncover an endogenous mechanism of echinocandin tolerance in A. fumigatus whereby the inducible oxylipin signal 5,8-diHODE confers protection against tip lysis via the transcription factor ZfpA. Treatment of A. fumigatus with echinocandins induces 5,8-diHODE synthesis by the fungal oxygenase PpoA in a ZfpA dependent manner resulting in a positive feedback loop. This protective 5,8-diHODE/ZfpA signaling relay is conserved among diverse isolates of A. fumigatus and in two other Aspergillus pathogens. Our findings reveal an oxylipin-directed growth program—possibly arisen through natural encounters with native echinocandin producing fungi—that enables echinocandin tolerance in pathogenic aspergilli.

Echinocandins are antifungal drugs that inhibit hyphal growth and induce lysis of hyphal tip compartments in pathogenic Aspergillus species. Here, Calise et al. show that echinocandins induce production of a fungal oxylipin signal, thus triggering hyphal growth changes that reduce hyphal tip lysis and confer echinocandin tolerance.

Details

Title
An oxylipin signal confers protection against antifungal echinocandins in pathogenic aspergilli
Author
Calise, Dante G. 1   VIAFID ORCID Logo  ; Park, Sung Chul 2   VIAFID ORCID Logo  ; Bok, Jin Woo 2 ; Goldman, Gustavo H. 3   VIAFID ORCID Logo  ; Keller, Nancy P. 4   VIAFID ORCID Logo 

 University of Wisconsin–Madison, Department of Medical Microbiology and Immunology, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675); University of Wisconsin–Madison, Microbiology Doctoral Training Program, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675) 
 University of Wisconsin–Madison, Department of Medical Microbiology and Immunology, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675) 
 Universidade de São Paulo, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Ribeirão Preto, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); National Institute of Science and Technology in Human Pathogenic Fungi, Ribeirão Preto, Brazil (GRID:grid.11899.38) 
 University of Wisconsin–Madison, Department of Medical Microbiology and Immunology, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675); University of Wisconsin–Madison, Department of Plant Pathology, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675) 
Pages
3770
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3050585353
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.